Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of adult patients with castration-resistant prostate cancer (CRPC), metastatic hormone-sensitive prostate cancer (mHSPC), and non-metastatic castration-resistant prostate cancer (nmCRPC). By binding to androgen receptors and inhibiting androgen receptor signaling, Xtandi helps prevent testosterone and other androgens from stimulating prostate cancer cell growth. It is taken orally, usually once daily, in combination with ongoing androgen deprivation therapy or surgical castration. Xtandi can be used in patients with or without prior chemotherapy and is often part of a comprehensive treatment plan aimed at slowing disease progression and improving survival outcomes.